Role of RASA1 in cancer: A review and update (Review)

YANHUA ZHANG1*, YUE LI1*, QUANYUE WANG2*, BO SU3,4, HUI XU1, YANG SUN1, PEI SUN3, RUMENG LI3, XIAOCHUN PENG3,5 and JUN CAI1

1Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434023; 2Qinghai Institute of Health Sciences, Xining, Qinghai 810000;
3Laboratory of Oncology, Center for Molecular Medicine; Departments of 4Pathology and 5Pathophysiology, School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, Hubei 434023, P.R. China

Received May 4, 2020; Accepted September 22, 2020

DOI: 10.3892/or.2020.7807

Correspondence to:
Dr Xiaochun Peng, Department of Pathophysiology, School of Basic Medicine, Health Science Center, Yangtze University, 1 Nanhuan Road, Jingzhou, Hubei 434023, P.R. China
E-mail: pxcwd789@sina.com
Dr Jun Cai, Department of Oncology, First Affiliated Hospital of Yangtze University, 1 Nanhuan Road, Jingzhou, Hubei 434023, P.R. China
E-mail: 529369023@qq.com

*Contributed equally

Abbreviations: RASA1, Ras p21 protein activator 1; CM-AVM, capillary malformation-arteriovenous malformation; KTWS, Klippel-Trenaunay-Weber syndrome; SWS, Sturgeon-Weber syndrome; VGAM, vein of Galen aneurysmal malformation; MEF2C-related disorders, myocyte enhancer factor 2C-related disorders; PKWS, Parkes-Weber syndrome; HHT, hereditary haemorrhagic telangiectasia; CM, capillary malformation; MAPK, mitogen-activated protein kinase; HUVECs, human umbilic vein endothelial cells; PI3K, phosphatidylinositol 3-kinase; PKB, protein kinase B; EPHB4, ephrin type-B receptor 4; FGF, fibroblast growth factor; Dok2, docking protein 2; MAP4K4, mitogen-activated protein kinase kinase kinase kinase 4; Ang II, angiotensin II; Btk, Bruton's tyrosine kinase; CRC, colorectal cancer; KRIT1, Krev interaction trapped protein 1; TGF-β, transforming growth factor-β; AMD, age-related macular degeneration; MDS, myelodysplastic syndromes; NF1, neurofibromatosis type one; FGFR-2, fibroblast growth factor receptor-2; PITX1, pituitary homeobox 1; CACNG4, calcium channel gamma subunit 4; BO-TCs, betel quid chewing-associated tongue carcinomas; GC, gastric cancer; ESCC, oesophageal squamous cell carcinoma cells

Key words: tumour, Ras p21 protein activator 1, microRNA, Ras, therapy

Abstract. Ras p21 protein activator 1 (RASA1) is a regulator of Ras GDP and GTP and is involved in numerous physiological processes such as angiogenesis, cell proliferation, and apoptosis. As a result, RASA1 also contributes to pathological processes in vascular diseases and tumour formation. This review focuses on the role of RASA1 in multiple tumours types in the lung, intestines, liver, and breast. Furthermore, we discuss the potential mechanisms of RASA1 and its downstream effects through Ras/RAF/MEK/ERK or Ras/PI3K/AKT signalling. Moreover, miRNAs are capable of regulating RASA1 and could be a novel targeted treatment strategy for tumours.

Contents
1. Introduction
2. RASA1 involvement in physiological processes
3. RASA1 involvement in pathological processes
4. RASA1 and cancers
5. Potential mechanism of RASA1 and tumorigenesis
6. Conclusion

1. Introduction

Ras p21 protein activator 1 (RASA1) is located on chromosome 5q14.3 and is a member of the RasGAP family which includes NF1, DAB2IP, and RASAL2 (1). RASA1 contains the following domains: Src homology 2 and 3 (SH2 and SH3), N-terminal C2A and C2B, GTPase -activating protein (GAP), and pleckstrin homology (PH), which is attached to a Bruton's tyrosine kinase (Btk) motif. RASA1 is a GAP with dual-specificity that enhances and accelerates the GTPase activity of Ras and Rap. Notably, intracellular Ca2+ levels regulate the GAP activity of RASA1. When Ca2+ concentrations are high, the C2 domains of Ras and Rap allow for the binding of phospholipids while the PH domain remains inactive and prevents lipid binding. RASA1 is normally located in the cytoplasm as a soluble protein and is recruited to the plasma membrane upon receptor-mediated increases in intracellular Ca2+ concentrations, which is attached to a Bruton's tyrosine kinase (Btk) motif. RASA1 is a GAP with dual-specificity that enhances and accelerates the GTPase activity of Ras and Rap. Notably, intracellular Ca2+ levels regulate the GAP activity of RASA1. When Ca2+ concentrations are high, the C2 domains of Ras and Rap allow for the binding of phospholipids while the PH domain remains inactive and prevents lipid binding. RASA1 is normally located in the cytoplasm as a soluble protein and is recruited to the plasma membrane upon receptor-mediated increases in intracellular Ca2+ concentrations (2). The RasGAP activity of RASA1 is increased when RASA1 associates with the membrane since RasGAP activity is limited in the soluble form of RASA1, although the underlying mechanism is not known (3). SH2-pTyr interaction allows for RASA1 to interact with p190RhoGAP (p190RhoGAP-A, ARHGAP35), which is a GAP for Rho (4). Due to its special
structure, RASA1 is involved in physiological functions such as cell growth, proliferation, differentiation, and apoptosis (Fig. 1). RASA1 mutation or epigenetic inactivation has been revealed in numerous human cancers, which has attracted interest for further investigation.

2. RASA1 involvement in physiological processes

Henkemeyer et al. first reported the physiological role of RASA1 as the regulation of embryonic blood vessel development (5). Ephrin type-B receptor 4 (EPHB4), which is a member of the receptor tyrosine kinase family, is a necessary factor for RASA1 during angiogenesis and studies have revealed that EPHB4 recruitment of RASA1 is required to restore blood flow in ischemia-reflow-injury in mice (6). RASA1 has been revealed to suppress RAS phosphorylation, which prevents Ras/MEK1/2/ERK1/2 and PI3K/Akt signalling and leads to a decrease in the growth and migratory capacities of vascular smooth muscle cells (7). The microRNA (miR)-132/212 cluster directly targets RASA1 and Sredp1, which modulates Ras-MAPK signalling and promotes arteriogenesis (8,9). The role of RASA1 and CDC42 in the control of endothelial cell (EC) tube network assembly has also been studied (10) and it has been revealed that RASA1 is essential for the survival of EC during developmental angiogenesis (11). Studies in human umbilical vein endothelial cells (HUVECs) have revealed that miR-4530 targeted RASA1 through ERK/MAPK and PI3K/AKT signalling and resulted in inhibition of proliferation and promotion of apoptosis and that miR-132 targeted RASA1 to promote angiogenesis in a myocardial infarction model (12,13).

The inhibition of Ras signal transduction by RASA1 has been revealed to negatively affect the maintenance of lymphatic vasculature by VEGFR-3 in a steady-state situation (14). RASA1 has also been revealed to directly interact with mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) for lymphatic vascular development (15-17).

RASA1 is necessary for the normal development and function of T cells and a study has revealed that RASA1-deficiency in mice increased apoptosis of CD4+CD8+ double-positive thymocytes (18). Motility of macrophages and cytoskeletal adhesion structures have been revealed to be modulated by RASA1-mediated translocation of p190RhoGAP (GRLF1) induced by BCL6 (19). RASA1 has been discovered to play a role in the development of neuron axons (20), dendritic cell differentiation (21), follicular development (22), epididymal development (23), skin wound healing (24,25), and stress (26) (Table 1).

3. RASA1 involvement in pathological processes

Since RASA1 is a central player of angiogenesis, studies have focused on RASA1 mutation or loss-of-function in vascular diseases such as capillary malformation-arteriovenous malformation (CM-AVM) syndrome, Klippel-Trenaunay-Weber syndrome (KTWS), Sturge-Weber syndrome (SWS), vein of Galen aneurysmal malformation (VGAM), MEF2C-related disorders, and Parkes-Weber syndrome (PKWS). Atypical capillary malformation (CM) is a key characteristic of CM-AVM and is frequently paired with multiple arteriovenous malformations (AVMs) and at least one of the following: Rapid vascular malformation, arteriovenous fistulas (AVFs), parkes Weber syndrome (PWS), and hereditary haemorrhagic telangiectasia (HHT) (27). CM usually manifests as multifocal wine spots on the skin due to inactivating mutations of RASA1 in 68% of cases (28). pi20RASGAP is encoded by RASA1 and directly affects EPHB4, which acts on capillaries, leading to HHT and CM (29,30). KTWS may rarely occur in the affected limb of patients with cutaneous haemangioma, venous varicosity, and hypertrophy of osseous-soft tissue (31). Mutations in RAP1A have been associated with KTWS and interact with RASA1 and Krev interaction trapped protein 1 (KRT1) (32,33). Patients with SWS harbour vascular malformations in the face, eyes, and brain due to a mutation in RASA1. The underlying mechanism is thought to be Nrf2-mediated oxidative stress, although the causal relationship has not been fully elucidated (34,35). VGAM encompasses a rare vascular malformation in the brain of children caused by RASA1, endoglin, and activin receptor-like kinase 1 (ACVRL1) mutations, which encode for ALK1 and SMAD4 (36,37). Patients with MEF2C-related disorders are severely intellectually impaired and have limited mobility and speech. In addition, they show hypotonia, seizures, and multiple minor anomalies of the brain. Moreover, RASA1 mutation and a decrease in MECP2 and CDKL5 expression have been correlated with this disease (38). PKWS is a rare vascular malformation syndrome with extensive capillary malformations that appear at birth or during early childhood and patients exhibit mutation of RASA1 that leads to a loss of function (39,40). ENG, ACVRL1, and SMAD4 are components of transforming growth factor-beta (TGF-β) signalling and mutations in these genes can cause HHT, which is the most commonly inherited vascular disorder. HHT has also been correlated with RASA1, BMP9, and GDF2 (32,35,41,42).

Cardiovascular and cerebrovascular diseases bring great pressure on countries with an ageing population. A previous study has revealed that RASA1 and its associated factors and vascular smooth muscle cell dysfunction through angiotensin II are central pathways involved in cardiovascular diseases. miR-132 was revealed to prevent CREB activation by angiotensin II via RASA1 (43). Myocardial fibrosis is an important process of cardiac hypertrophy and heart failure, which has been correlated to an upregulation of RASA1 via miR-21 (44,45). Obesity is a risk factor for cardiovascular disease and a study has demonstrated that PPARγ/miR-223 participates in the deposition of adipocytes by targeting RASA1 (46). Another study has linked tricuspid atresia, a congenital heart defect with fatal consequences, with the homozygous RASA1 germline mutation c.1583A>G (p.Tyr528Cys) (47). An animal model of cerebral ischemia has revealed that the GAS5/miR-335/RASA1 axis is regulated to inhibit neuron apoptosis and promote neuroprotection (48).

Chronic kidney disease is related to renal fibrosis and miR-132 has been revealed to inhibit the development of renal fibrosis by targeting RASA1, leading to reduced proliferation of myofibroblasts (49). A leading cause of blindness is age-related macular degeneration (AMD), where studies have revealed abnormal expression of RASA1 in OXYS rats (50). Myelodysplastic syndromes (MDS) encompass a group of haematopoietic stem cell disorders that are characterised
by abnormal myeloid cell differentiation and development, ineffective haematopoiesis, refractory haemocytopenia, and haemopoietic failure. Notably, it has been revealed that MDS is related to RASA1 downregulation (51). In a mouse model for CCI-induced neuropathic pain, intrathecal injection of miR-144 mimics reduced the mechanical and thermal pain experienced by mice through the downregulation of RASA1 (52) (Table II).

4. RASA1 and cancers

Investigation into changes in genomic DNA and RNA in HL-60 cells revealed that RASA1 is related to tumorigenesis (53). The Ras-GAP SH3 domain inhibits Rho-GAP activity and inhibits tumour development (54). RASA1 has also been reported as an oncogene through large-scale tumour sequencing studies that are based on 3D mutation clusters in relation to the protein structure (55).

In tumour development, mutations of Ras at residues 12, 13, or 61 affect the activity of intracellular guanosine triohosphite (GTP), which alternates between GDP and GTP forms and activates RasGAP proteins and Ras by Ras GTPase, regulating the guanine nucleotide exchange factors (RasGEFs). The understanding of RASA1 and its relationship with tumour formation is qualitative and is limited to the abnormal expression of RASA1 and several other genes from the sequencing of certain tumours. It has been revealed that abnormal or downregulation of RASA1 expression affects tumorigenesis and the continued technological development in the field of molecular biology allows for more in-depth research, where it has been found that the expression of RASA1 in most tumour cells is associated with intracellular miRNA. Furthermore, a small portion of tumorigenesis may be due to the coupling of RASA1 to its associated protein or gene (56). Nevertheless, the role of RASA1 in tumour formation requires further study.

Lung cancer. Lung cancer incidence and deaths continue to rise and place high pressure on health care with its high incidence (2.09 million new cases in 2018 vs. 1.8 million in 2012) and mortality rate (1.76 million deaths in 2018 vs. 1.6 million in 2012) compared with other tumours (57). The occurrence of lung cancer has been linked to RASA1 mutations by next-generation sequencing (58,59). Zhu et al revealed that hsa-miR-182 downregulated RASA1 to suppress proliferation of lung squamous cell carcinoma through tissue microarray and quantitative PCR (60). Recently, Shi et al demonstrated that miR-30c and miR-21 were significantly upregulated by two KRAS isoforms in small-cell lung cancer and induced drug resistance by inhibiting key tumour suppressor genes such as neurofibromatosis type one (NF1), RASA1, BID, and RASSF8 (61). Mutations of EGFR result in drug resistance...
and relapse in patients with non-small cell lung cancer (NSCLC) (62). Furthermore, miR-31 directly inhibits the expression of RASA1 and FIH-1, leading to at least partial activation of Raf/MEK/ERK and PI3K/Akt signalling in gefitinib-resistant NSCLC (63). Kitajima and Barbie classified NF1 or RASA1 mutations in small-cell lung carcinoma and proposed the clinical evaluation of MAPK inhibition in an analysis of large genomic datasets of NSCLC [MSK-IMPACT dataset at MSKCC (n=2,004) and TCGA combined lung cancer dataset (n=1,144)] (64). RASA1 and NF1 mutations are strong drivers of NSCLC (65). Fibroblast growth factor receptor-2 (FGFR-2) is a tyrosine kinase receptor, which can selectively bind to fibroblast growth factor (FGF) to promote autophosphorylation and mediate cell response through downstream MAPK and Akt signalling. A previous study has revealed that FGFR-2 mutation is an important driver of lung cancer, which has become a key target of lung cancer drug development. In an FGFR2-mutant resistant model, RASA1 was found to be inactivated (66).

Colorectal cancer. The incidence of colorectal cancer (CRC) is rising and is predicted to increase to 2.5 million new cases by 2035 and is ranked third among malignant tumours across the world and second in some developing areas (67,68). Colorectal specimens including 468 colorectal tumour samples from a large personalised medicine initiative and 17 paired primary-metastatic and 2 metastatic-metastatic specimens from 18 CRC patients were analysed by next-generation sequencing to reveal the presence of RAS1 mutations (69). RASA1 expression has been linked to multiple miRNAs in colorectal cancer. In vivo, miR-31 has been revealed to be negatively correlated with RASA1 protein level and miR-31 was a key player in RAS signalling activation through the inhibition of RASA1 translation, resulting in accelerated growth of colorectal cancer cells and stimulation of tumour formation (70). In rectal cancer cells, expression of miR-21 reduced the expression level of RASA1 resulting in the promotion of cell proliferation, anti-apoptosis, and tumour cell formation (71). RASA1 encoding RAS GTPase is one of the target genes that is continuously downregulated in cells overexpressing miR-21 and upregulated in cells exposed to miR-21 inhibitors (72). These results coincide with a study by Sun et al in which upregulation of miR-223 can be detected in colon cancer cells and promotes tumour growth. Conversely, miR-223 inhibition may reduce orhalt the growth of solid tumours (73). miR-335 has been revealed to inhibit the expression of the RASA1 gene by targeting a specific sequence of the 3'UTR of RASA1. Low expression of RASA1 has been revealed to promote tumour cell development and miR-335 expression was increased in patients with CRC compared with normal mucosa, whereas high expression of miR-335 was significantly associated with tumour size and CRC differentiation. miR-335 overexpression in CRC cells was revealed to promote cell proliferation and tumour growth in vivo (74). Antoine-Bertrand et al observed an interaction between pl20RasGAP and cancer cells in CRC, which regulates axonal growth mediated by netrin-1 and guides the development of cortical neurons in embryos (75). KRAS mutations are found in 40% of patients with CRC and the effective treatment of CRC with late KRAS mutation is limited at present (76). RASA1 is as an effector of KRAS mutation and may play an important role as a drug treatment target (77). However, studies using CRISPR technology have described that only loss of NF1 promotes resistance to EGFR inhibition (78).

Liver cancer. Primary liver cancer has the seventh-highest incidence (0.84 million new cases in 2018 year) and second highest mortality (0.78 million deaths in 2018) worldwide (79). China has the highest prevalence owing to an increased prevalence of 18.3 per 100,000 and its population of 1.4 billion (80). Mutations of RASA1 have been found by detecting RASA1 and other members of the RasGAP family
through sequencing of liver cancer tissue genes (81). The analysis of RASA1 expression and the prognosis of patients revealed that the expression of RASA1 was closely related to tumour size and differentiation and that the prognosis was poor with low RASA1 expression, indicating that RASA1 could be a predictive factor for the prognosis of patients with liver cancer (82). RASA1 is also regulated by miRNA although other potential oncopgenes also contribute to the development of liver cancer. Increased miR-31 expression and low RASA1 expression have been detected in cells and tissues from liver cancer patients. Furthermore, it has been confirmed that miR-31 promotes cellular proliferation and inhibits liver cancer cells apoptosis by downregulating RASA1 expression (83). When liver cancer cells are exposed to a hypoxic environment, a significant increase in miR-182 expression occurs, which then promotes angiogenesis via RASA1 and leads to proliferation of cancer cells (84). Thus, RASA1 levels are related to liver cancer cell proliferation. In addition, RASA1 is regulated by pituitary homeobox 1 (PITX1) and protein tyrosine phosphatase 1B (PTP1B). PITX1 has a tumour suppressing function through the regulation of RasGAP expression. PITX1 is downregulated by PTP1B, which drives proliferation and inhibits apoptosis of tumour cells by acting on RASA1 (85). In cells exposed to mild stress, RASA1 is cleaved into an N-terminal fragment (fragment N) by caspase-3, which potently inhibits the activity of NF-κB by augmenting its translocation to the cytoplasm (26). Studies have revealed that liver cancer incidence is reduced by the caspase-3/p120 RasGAP stress-sensing module. However, the overall survival is not affected (26,86).

Breast cancer. Breast cancer is the second leading cause of cancer-related deaths in women (2.08 million new cases and 0.62 million deaths in 2018) and although the genotyping of breast cancers and the subsequent targeted treatment significantly improve the curative rate to more than 65%, it remains necessary to discover more tumour markers for further treatment optimisation (79,87). Some studies have shown that the low expression of RASA1 is related to the occurrence of breast cancer (88,89). This is consistent with a study that demonstrated the presence of 7 genetic mutations in breast cancer, which included RASA1 mutations (90). The expression of RASA1 is prevalent in triple-negative breast cancer (TNBC) tumours and tumour cells with low estrogenic receptor expression (91). Both docking protein 2 (Dok2) and RASA1 function as tumour suppressors and have been detected in several types of solid tumours. Our previous study revealed that a weak Dok2/RASA1 expression was associated with poorly differentiated breast adenocarcinoma. Moreover, a decrease in Dok2 and RASA1 expression was linked to larger tumour size and a heightened chance of metastasis to the axillary lymph node (92). RASA1 is also regulated by miRNA and other potential oncopgenes contribute to the development of breast cancer. miR-206/21 has been revealed to promote the growth of hepatoma cells by inhibiting the translation of RASA1 and promoting Ras/Erk signal transduction and cell differentiation (92). miR-421 which targets RASA1, has been revealed to inhibit TNBC tumour growth and metastasis (93). As C2 domains of RASA1 participate in the regulation of calcium signalling, L-type voltage-gated calcium channel gamma subunit 4 (CACNG4) can promote the stability of the internal environment of breast cancer cells and improve the survival and metastasis ability of tumour cells through alternating calcium signalling events and invading key survival and metallic pathway genes including RASA1 (94).

Gynaecologic tumours. RASA1 mutation and abnormal expression is also regarded as a contributing factor to the development of gynaecologic tumours such as cervical and ovarian cancer (95,96). The incidence (98,900 new cases in 2015) of cervical cancer in China has been ranked second in the world after Chile with a clear trend towards younger age of onset (97). However, research examining the relationship between cervical cancer and RASA1 is limited. Zhang et al revealed that miR-21 was highly expressed in the serum of cervical cancer patients compared with healthy control subjects. In addition, the cervical cancer cell lines HeLa and HT-3 were used and it was revealed that miR-21 decreased the expression of RASA1, which led to increased cell proliferation and migration via Ras-induced epithelial-mesenchymal transition (95). In the development of ovarian cancer, the circular RNA circ-ITCH was revealed to extensively inhibit the viability and motility of ovarian cancer cell lines SK-OV-3 and Caov-3 and dampens tumorigenesis in xenografted NOD mice by upregulating RASA1 expression (96).

Leukaemia. Leukaemia (0.43 million new cases and 0.31 million deaths in 2018) is the most common type of cancer in children and young adults, highlighting the importance of discovering novel tumour markers for early diagnosis (79). Scans at DNA and RNA levels using microarray technology in HL-60 cells have demonstrated that RASA1 is a candidate cancer-related gene (53). Lubeck et al confirmed that a lack of RasGAP alone in T cells in RASA1 and NF1 double-deficient mice leads to the development of T cell acute lymphoblastic leukaemia/lymphoma (98). Falconi et al revealed that RASA1 was downregulated and inhibited MSC clone formation in acute myeloid leukaemia patients (51). RASA1 has been revealed to be regulated by miR-223 although the mechanism in leukaemia requires further research (99).

Ovary squamous cell carcinomas (OSCCs). OSCCs are a group of aggressive tumours known for their rapid spread to the lymph nodes and a high treatment failure rate. In addition, the incidence rate of OSCC is increasing (incidence increase ranging from 0.4 to 3.3% per year) among young people below the age of 50 (100). By sequencing the entire genome of 50 paired primary tumours of the tongue and 120 OSCC from male individuals in Taiwan, it has been revealed that RASA1 variants are related to cigarette smoking, betel nut chewing, human papillomavirus infection, and tumour stage (101,102). The development of betel quid chewing-associated tongue carcinomas has been revealed to be related to mutations in RASA1 in and CpG islands (103). The expression of miR-182 in OTSCC was revealed to be significantly upregulated, and negatively correlated with RASA1 levels, suggesting that the miR-182/RASA1 axis is a potential target for the treatment of OSCC (104).
Other cancers. While pancreatic cancer is not as common as other tumours, the outcome is markedly poor (105). In pancreatic cancer, several gene mutations including RASA1 are more pronounced (106). Kent et al reported that the expression of RASA1 was decreased in pancreatic cancer cells and further study revealed that RNAi knockdown of RASA1 significantly enhanced the progression of pancreatic cancer for both Capan-1 and MiaPaCa2 cell lines consistent with the miR-31 overexpression phenotype (107).

Prostate cancer incidence is high in Europe and North America with ~0.45 million and 0.23 million new cases in 2018, respectively (108). RASA1 has been discovered to be a potential target gene for advanced drug-resistant recurrent prostate cancer by whole transcriptome sequencing (109). In a genome-wide association study that included 12,518 cases of prostate cancer, RASA1 was revealed to be associated with aggressive prostate cancer while it exhibited no association with nonaggressive prostate cancer (110).

Melanoma samples in patients with metastatic disease often exhibit a loss of RASA1 expression and low RASA1 mRNA has been linked to a decrease in overall survival in patients with BRAF-mutated melanoma (111,112).

In thyroid or gastroenteropancreatic neuroendocrine tumours, the relationship between BRAF and multiple gene mutations including RASA1 has been documented (113,114). Kidney cancer has many subtypes with a clear increasing trend in the incidence in the United States. A similar rise in incidence is also seen in Chinese men. In renal clear cell carcinoma, QKI-5-stable RASA1 mRNA has been found to directly bind to the reactive elemental region of RASA1 QKI and subsequently prevents the activation of the RAS-MAPK signalling, leading to inhibition of cell growth and inducing cell cycle arrest (115). Another study revealed that RASA1 may play a key role in the progression of RCC by decreasing miR-223-3p and subsequently increasing F-box/WD repeat-containing protein 7 (FBXW7) expression (116).

Gastric cancer (GC) is ranked third in mortality among all cancers (79). The incidence of gastric cancer in China is more pronounced in rural areas and is one of the primary malignant tumours which accounts for a marked 42.5% of worldwide GC cases and 45.0% of worldwide deaths that endanger public health (117). Mutations in RASA1 are also present in gastric cancer. Li et al revealed that low miR-335 expression accelerated the invasion and metastasis of cancer cells. Furthermore, miR-335 can be silenced by promoter hypermethylation and is heavily involved in metastatic gastric cancer through its target genes such as RASA1 (118). In oesophageal squamous cell carcinoma cells (ESCC), high expression of miR-21 was revealed to significantly downregulate the expression of RASA1 (119). Mutation or aberrant expression of RASA1 has also been revealed to be related to the development of cutaneous squamous cell carcinoma and sarcoma (120,121).

RASA1 and related factors in various cancers are presented in Table III.

### Table III. RASA1 with multiple gene proteins and related cancers.

| Cancers                      | RASA1 associated gene or protein (Refs.) |
|------------------------------|----------------------------------------|
| Lung cancer                  | RASA1, hsa-miR-182, miR-31, miR-30c, miR-21, NF1 (58-66) |
| Colorectal cancer            | RASA1, miR-31, miR-21, miR-335, miR-223, K-RAS, Netrin-1, NF1 (69-78) |
| Liver cancer                 | RASA1, miR-31, miR-182, PITX1, caspase-3 (26,81-86) |
| Breast cancer                | RASA1, miR-206/21, miR-421, CACNG4 (88-94) |
| Gynecologic tumors           | RASA1, miR-21, circ-ITCH, miR-145 (94,96) |
| Leukemia                     | RASA1, miR-223 (51,53,98,99) |
| Oral tongue squamous cell carcinomas | RASA1, miR-182 (101-104) |
| Pancreatic cancer            | RASA1, miR-31 (106,107) |
| Prostate cancer              | RASA1 (109,110) |
| Melanoma                     | RASA1, hsa-miR-223, hsa-miR-23b (111,112) |
| Thyroid cancer               | RASA1, BRAF (113,114) |
| Renal clear cell carcinoma   | RASA1, QKI-5, miR-223-3p (115,116) |
| Gastric cancer               | RASA1, miR-335 (118) |
| Esophageal cancer            | RASA1, miR-21 (119) |
| Cutaneous squamous cell carcinoma | RASA1 (120) |
| Sarcoma                      | RASA1, BRAF (121) |

RASA1, Ras p21 protein activator 1; miR, microRNA; NF1, neurofibromatosis type one; PITX1, pituitary homeobox 1; CACNG4, calcium channel gamma subunit 4.

5. Potential mechanism of RASA1 and tumorigenesis

Ras can be activated by inhibiting RasGAPs and increases tumour development risk (122). In this review, we revealed
that mutations or aberrant expression of RASA1 are present in almost all cancers and tumour cells and that during the development of tumours, Ras/Raf/MEK/ERK play a central role (59,78,104). This signalling pathway is connected by small GTP protein-membrane binding ligands that initiate a cascade of receptor tyrosine kinases and cytoplasmic proteins. The first protein kinase RAF in the RAS recruitment cascade is activated after GTP binding on the cell membrane through a series of complex processes including changing the phosphorylation state of the protein and binding with the skeleton protein and other kinases. The activated Raf kinase continues to phosphorylate and activate MAPKK protein kinase MEK1/2 and finally phosphorylates and activates ERK1/2, inducing abnormal proliferation, invasion, growth, and distant metastasis of malignant tumours (75,123). In addition, loss of RASA1 function can enhance RAS-ERK signal amplification (66,78). PI3K/AKT have been described as key regulators of cell proliferation and differentiation and are involved in tumour cell proliferation, invasion, and metastasis (124). Some studies have revealed that aberrant RASA1 expression activates PI3K/AKT signalling (51,63,64). Moreover, numerous miRNAs have been revealed to regulate RASA1 expression in several cancers such as lung, colorectal, hepatocellular, and triple-negative breast cancers (60,70,83,91). The miRNA/RASA1 axis is an attractive target for tumour treatment and its effectiveness has been demonstrated in numerous studies (60,67,71,83,92). miRNAs are capable of regulating RASA1 and could be a novel targeted treatment strategy for tumours. Numerous miRNAs have been revealed to be involved in different cancers, such as miR-21 in lung cancer, and thus these miRNAs should be focused on as targeted treatments (125). Various genes or proteins such as RASA1 have fundamental roles at normal levels, however an imbalance of these genes or proteins has been revealed to result in disease or tumors, therefore, targeted therapies such as oncolytic viruses can correct local discordance and treat tumors without affecting overall function (Fig. 2).

6. Conclusion

Although RASA1 primarily participates in angiogenesis and vascular-related diseases, whole-genome sequencing confirmed the importance of RASA1 in tumorigenesis, invasion, metastasis, and drug resistance (120). RASA1 was first reported in blood vessel development or angiogenesis and its other functions including antitumor have been gradually revealed, RASA1 play the similar role in physiological process such as angiogenesis, vascular-related diseases or cancers, only the outcome are not same. Normal or balanced expression levels of RASA1 promote normal blood vessel development; aberrant or imbalanced RASA1 expression levels result vascular-related diseases such as CM-AVM or KTWS (40,126). RASA1 has more than one mechanism of action in the development of cancers. In some cancers, the role of RASA1 is more profound and precise (127). From these pathways, we can conduct genetic screening or testing, including RASA1 testing in serum, before the cancer fully develops to achieve early detection and prevention of cancer. Furthermore, these findings may lead to the development of novel drugs that halt cancer progression by blocking the pathways it uses for growth and dissemination. In addition, RASA1 also serves as a good reference for the prognosis of cancer after surgery and treatment. Therefore, for some cancers with a less clear mechanism of action, the aberrant expression of RASA1 may be used to advance cancer treatment strategies.
Acknowledgements

Not applicable.

Funding

The present study was supported by the Nature Science Foundation of Hubei Province (grant no. 2017CFB786), the Hubei Province Health and Family Planning Scientific Research Project (grant no. WJ2016Y10), the Jingzhou Science and Technology Bureau Project (grant no. 2017-93), and the National innovation and entrepreneurship training program for College Students (grant no. 202010489017). All funding was provided to XP.

Availability of data and materials

Data sharing is not applicable to this article, as no datasets were generated or analyzed during the present study.

Authors' contributions

XP designed and supervised the study. YZ, YL, BS, HX and YS reviewed the references. YZ, YL and QW performed the research. YZ, XP and JC wrote the manuscript. YZ, PS and RL YS reviewed the references. YZ, YL and QW performed the research. YZ, XP and JC wrote the manuscript. YZ, PS and RL contributed to tables and figures. XP and JC acquired funding.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing of interests

The authors declare that they have no competing interests.

References

1. Harrell Stewart DR and Clark GF: Pumping the brakes on RAS-negative regulators and death effectors of RAS. J Cell Sci 133: jcs238865, 2020.
2. Dai Y, Walker SA, de Vet E, Cook S, Welch HC and Locker P: Ca2+-dependent monomer and dimer formation switches CAPRI Protein between Ras GTPase-activating protein (GAP) and RapGAP activities. J Biol Chem 286: 19905-19916, 2011.
3. Sot B, Behrmann E, Raunser S and Wittinghofer A: Ras switches CAPRI Protein between Ras GTPase-activating (RasGAP) activity of the dual specificity protein (GAP) and RapGAP activities. J Biol Chem 286: 19740-19749, 2011.
4. Roth Flach RJ, Guo CA, Danai LV, Yawee JC, Gujja S, Edwards YJ and Czech MP: Endothelial Mitogen-activated protein kinase kinase kinase kinase 4 is critical for lymphatic vascular development and function. Mol Cell Biol 36: 1740-1749, 2016.
5. Lapinski PE, Lubeck BA, Wilkinson JE, Srinivasan RS, Sevick-Muraca E and King PD: RASA1 maintains the lymphatic vasculature in a quiescent functional state in mice. J Clin Invest 122: 733-747, 2012.
6. Castorena-Gonzalez JA, Srinivasan RS, King PD, Simon AM and Davis MJ: Simplified method to quantify valve Back-leak uncovers severe mesenteric lymphatic valve dysfunction in mice deficient in connexins 43 and 37. J Physiol 598: 2297-23102, 2020.
7. Hu X, Wang Z, Wu H, Jiang W and Hu R: Ras ssDNA aptamer inhibits vascular smooth muscle cell proliferation and migration through MAPK and PI3K pathways. Int J Mol Med 35: 1355-1361, 2015.
8. Lei Z, van Mil A, Brandt MM, Grundmann S, Hoefler I, Smits M, El Azzouzzi H, Fukuo T, Cheng C, Doevendans PA, et al: MicroRNA-132/212 family enhances arteriogenesis after hindlimb ischaemia through modulation of the Ras-MAPK pathway. J Cell Mol Med 19: 1994-2005, 2015.
9. Anandi S, Majeti BR, Accardo LM, Murph AA, Mukthavaram R, Scheppke L, Huang M, Shields DJ, Lindquist JN, Lapinski PE, et al: MicroRNA-132-212 regulates loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 16: 909-914, 2010.
10. Andrus PR, Kim EJ, Barry DM, Cleaver OB and Davis GE: Cdc42 and k-ras control endothelial tubulogenesis through apical membrane and cytoskeletal polarization: Novel stimulatory roles for GTPase effectors, the small GTPases, Rac2 and Rap1b, and inhibitory influence of Arhgap31 and Rasa1. PLoS One 11: e0147758, 2016.
11. Chen D, Teng JM, North PE, Lapinski PE and King PD: RASA1-dependent cellular export of collagen IV controls blood and lymphatic vascular development. J Clin Invest 130: 3545-3561, 2019.
12. Jing L, Li H, Zhang T, Lu J and Zhong L: MicroRNA-4530 suppresses cell proliferation and induces apoptosis by targeting RASA1 in human umbilical vein endothelial cells. Mol Med Rep 19: 3393-3402, 2019.
13. Ma T, Chen Y, Chen Y, Meng Q, Sun J, Shao L, Yu Y, Huang H, Hu Y, Yang Z, et al: MicroRNA-132, delivered by mesenchymal stem cell-derived exosomes, promotes angiogenesis in myocardial infarction. Stem Cells Int 2018: 3290372, 2018.
14. Lapinski PE, Kwon S, Lubeck BA, Wilkinson JE, Srinivasan RS, Sevick-Muraca E and King PD: RASA1 maintains the lymphatic vasculature in a quiescent functional state in mice. J Clin Invest 122: 733-747, 2012.
15. Staicu DI, Gavrusea M, Calin GA, Huard J, Edelmann W, Ma B, Fukuoka T, Wu Y and Hwang DS: MicroRNA-132 mediates the anti-inflammatory effects of mesenchymal stem cells. Stem Cells Transl Med 5: 511-522, 2016.
2394

26. Khalil H, Loukili N, Regamey A, Cuesta-Marban A, Santori E, Huber M and Widmann C: The caspase-3-p120-RasGAP module generates a NF-kB repressor in response to cellular stress. J Cell Sci 126: 3502-3513, 2013.

27. Wooster-Donahue WL, Johnson P, McDonald J, Blei F, Berenistein A, Sorscher M, Mayer J, Scheuere AE, Lewis T, Grimmer JF, et al: Expanding the clinical and molecular findings in RASAI capillary malformation-arteriovenous malformation. Eur J Hum Genet 26: 1521-1536, 2018.

28. Revencu N, Boon LM, Mendola A, Cordisco MR, Dubois J, Clapuyt P, Hammer F, Amor DJ, Irvine AD, Baselga E, et al: RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformation. Hum Mutat 34: 1632-1641, 2013.

29. Yu J, Streicher JL, Medline L, Krantz ID and Yan AC: EPHB4 Mutation implicated in capillary malformation-arteriovenous malformation syndrome: A case report. Pediatr Dermatol 34: e227-e230, 2017.

30. Amyere M, Revencu N, Helaers R, Pairet E, Baselga E, Cordisco M, Chung W, Dubois J, Lacour JF, Martorell L, et al: Germline Loss-of-function mutations in EPHB4 cause a second form of capillary Malformation-arteriovenous malformation (CM-AVM2) Deregulating RAS-MAPK signaling. Circulation 136: 1037-1048, 2017.

31. Pérez-Ayafaye R, Martínez-Moreno N, Rosati SD, Moreu-Garcia C and Martínez-Alvarez R: Klippel-Trenaunay-Weber syndrome associated with multiple cerebral arteriovenous malformations: Usefulness of Gamma Knife stereotactic radiosurgery in this syndrome. World Neurosurg 141: 425-429, 2020.

32. Bourtarouch M, Ben Salem D, Giré L, Giroud M, Béjot Y and Ricolfi F: Multiple cerebral and spinal cord cavernomas in Klippel-Trenaunay-Weber syndrome. J Clin Neurosci 17: 1073-1075, 2010.

33. Karadag A, Senoglu M, Sayhan S, Okremolidize L and Middlebrooks EH: Klippel-Trenaunay-Weber syndrome with atypical presentation of cerebral cavernous angiomia: A case report and literature review. World Neurosurg 126: 354-358, 2019.

34. Zhou Q, Zheng JW, Yang XJ, Wang HJ, Ma D and Qin ZP: Detection of RASA1 mutations in patients with sporadic Sturge-Weber syndrome. Childs Nerv Syst 27: 603-607, 2011.

35. Kadam SD, Gucek M, Cole RN, Watkins PA and Comi AM: Cell proliferation and oxidative stress pathways are modified in fibroblasts from Sturge-Weber syndrome patients. Arch Dermatol Res 304: 229-235, 2012.

36. Chida A, Shintani M, Wakamatsu H, Tsutsui Y, Izuka Y, Kawaguchi N, Furutani Y, Inai K, Nonoyama S and Nakashish F: ACVRL1 gene variant in a patient with Klippel-Trenaunay malformation. J Pediatr Genet 2: 181-189, 2013.

37. Komiyama M, Miyatake S, Terada A, Ishiguro T, Ichiba H and Kozhevnikova OS: Identification of functional networks associated with cell death in the retina of OXYS rats during the development of retinopathy. Cell Cycle 14: 3544-3556, 2015.

38. Falcioni G, Fabiani E, Testoni L, Criscuolo M, Raffaelli C, Bellesi S, Hohaus S, Vos MO, d’Alo F and Leone G: Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes. Exp Hematol 44: 75-83.e1-e14, 2016.

39. Zhang X, Guo H, Xie A, Liao O, Ju F and Zhou Y: MicroRNA-144 relieves chronic constriction injury-induced neuropathic pain via targeting RASA1. Biotechnol Appl Biochem 67: 294-302, 2020.

40. Ulger C, Toruner GA, Alkan M, Mohammed M, Damani S, Kang J, Galante A, Aviv H, Sotereopoulos P, Tolias PP, et al: Comprehensive genome-wide comparison of DNA and RNA level scan using microarray technology for identification of candidate Cancer-related genes in the HL-60 cell line. Cancer Genet Cytofgenet 147: 28-35, 2003.

41. Yang XY, Guan M, Vigil D, Der CJ, Elliott AM: Mutations in RASA1 and inhibited its RhoA GTase and growth-suppressing activities. Oncogene 28: 1410-1409, 2009.

42. Kamburov A, Lawrence MS, Polak P, Leschker I, Lage K, Golub TR, Lander ES and Getz G: Comprehensive assessment of cancer missense mutation clustering in protein structures. Nat Genet 41: 45-50, 2009. Epub 2008-11-26.

43. Li L, Fan Y, Huang X, Luo J, Zhong L, Xu LS, Lu L, Xiang T, Chan ATC, Yeo W, et al: Tumor suppression of Ras GTase-activating protein RAS45 through antagonizing Ras signaling perturbation in carcinomas. Science 21: 1-18, 2019.

44. Bade BC and Dela Cruz CS: Lung cancer 2020: Epidemiology, Etiology, and prevention. Clin Chest Med 41: 1-24, 2020.

45. Liu X, Jia Y, Stoopper MB, Shen Y, Cheng H, Chen J, Mansukhani M, Koul S, Halmos B and Borczuk AC: Next-generation sequencing of pulmonary sarcomatoid carcino- ma reveals high frequency of actionable MET gene mutations. J Clin Oncol 34: 794-802, 2016.

46. Campbell JD, Alexandre A, Kim J, Wala J, Berger AH, Pedamalulu CS, Shukla SA, Guo G, Brooks AN, Murray BA, et al: Distinct patterns of somatic genome alterations in lung adenocarci- noma and squamous cell carcinomas. Nat Genet 48: 607-616, 2016.

47. Zhu YJ, Xu B and Xia W: Hsa-mir-182 downregulates RASA1 expression in osteosarcoma cells. Oncology 2019: 181-190, 2019.

48. Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Leevy JS, Su WC, Kowalski D, et al: Osimertinib plus sunitinib in patients with EGFR mutation-positive, MET-amplified, Non-small-cell lung cancer: Progression-free survival analysis of the phase 1b study. Lancet Oncol 20: 373-386, 2020.
63.  Sun D, Wang C, Long S, Ma Y, Guo Y, Huang Z, Chen X, He J, Jin S, Zhang W, Wu D, Li J, Xu J and Gao W: Long CROCKETT SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

64.  Dekker E, Tanis PJ, Vleugels JA, Kasi PM and Wallace MB: Colorectal cancer. Lancet 394: 1467-1480, 2019.

65.  Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M and Phillips C, et al: Transcriptomics and transposon mutagenesis identify complex mechanisms of resistance to the FGFR Inhibitor AZD4547. Cancer Res 78: 5668-5679, 2018.

66.  Crockett SD and Nagtegaal I: KRAS status as a predictor of prognosis in colorectal cancer. J Exp Clin Cancer Res 34: 67, 2015.

67.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

68.  Dekker E, Tanis PJ, Vleugels JA, Kasi PM and Wallace MB: Colorectal cancer. Lancet 394: 1467-1480, 2019.

69.  Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M and Phillips C, et al: Transcriptomics and transposon mutagenesis identify complex mechanisms of resistance to the FGFR Inhibitor AZD4547. Cancer Res 78: 5668-5679, 2018.

70.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

71.  Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M and Phillips C, et al: Transcriptomics and transposon mutagenesis identify complex mechanisms of resistance to the FGFR Inhibitor AZD4547. Cancer Res 78: 5668-5679, 2018.

72.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

73.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

74.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

75.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

76.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

77.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

78.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

79.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

80.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

81.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

82.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

83.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

84.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

85.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

86.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

87.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

88.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

89.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

90.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

91.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

92.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.

93.  Crockett SD and Nagtegaal I: Terminology, molecular features, and epidemiology of serrated colorectal neoplasia. Gastroenterology 157: 949-966, 2019.
104. Wang J, Wang W, Li J, Wu L, Song M and Meng Q: miR182 activates the Ras-MEK-ERK pathway in human oral cavity squamous cell carcinoma by suppressing RASA1 and SPRED1. Oncol Targets Ther 10: 667-679, 2017.

105. Mizrahi JD, Surana R, Valle JW and Shroff RT: Pancreatic cancer. Lancet 395: 2008-2020, 2020.

106. Rajamani D and Bhasin MK: Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis. Genom Med 8: 38, 2016.

107. Kent OA, Mendell JT and Rottapel R: Transcriptional regulation of mir-31 by oncogenic KRAS mediates metastatic phenotypes by repressing RASA1. Mol Cancer Res 14: 267-277, 2016.

108. Culp MB, Soerjomataram I, Efstathiou JA, Bray F and Jamal A: Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 77: 38-52, 2020.

109. Sowalsky AG, Xia Z, Wang L, Zhao H, Chen S, Bubley GJ, Kent OA, Mendell JT and Rottapel R: Transcriptional regulation of mRNA . Cell Cycle 15: 3094-3104, 2016.

110. Kanchi KL, Wang X, Hill KS, Messina JL, Lee JH, et al: BRAFV600E-associated gene expression patterns to enhance the understanding of regulatory mechanisms in diseases. BMC Bioinformatics 13: 36, 2012.

111. Sears R and Gray JW: Epigenomic inactivation of RasGAPs activates RAS signaling in a subset of luminal b breast cancers. Cancer Discov 7: 131-133, 2017.

112. Degenmenci U, Wang M and Hu J: Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Cells 9: 198, 2020.

113. Markou A, Zavridou M and Lianidou ES: miRNA-21 as a novel therapeutic target in lung cancer. Lung Cancer (Auckl) 7: 19-27, 2016.

114. Liu Z, Deng M, Wu L and Zhang S: An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes. Mol Med 26: 48, 2020.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.